Literature DB >> 18818377

Foxp3+ T-regulatory cells in Sjogren's syndrome: correlation with the grade of the autoimmune lesion and certain adverse prognostic factors.

Maria I Christodoulou1, Efstathia K Kapsogeorgou, Niki M Moutsopoulos, Haralampos M Moutsopoulos.   

Abstract

Sjögren's syndrome (SS) is a chronic autoimmune exocrinopathy associated with variable lymphocytic infiltration of the affected organs (primarily salivary and lacrimal glands) and broad clinical manifestations, including lymphoma development. To investigate the potential implication of Foxp3(+) T-regulatory cells in the regulation of SS inflammatory responses, we studied their incidence in the minor salivary glands (MSGs) and their relationship with histopathological and clinical disease parameters. Similar percentages of infiltrating Foxp3(+) cells were observed in the MSG lesions of all SS patients (n = 30) and non-SS sialadenitis controls (n = 7). Foxp3(+) cells were not detected in sicca-complaining controls with negative biopsy (n = 6). In SS patients, Foxp3(+) cell frequency varied according to lesion severity, with the highest and lowest frequencies obtained in intermediate and mild MSG lesions, respectively. In the peripheral blood of these patients, reverse distribution of Foxp3(+) cells was observed. Furthermore, the frequency of Foxp3(+) cells in the MSG lesions and peripheral blood was negatively associated (r = -0.6679, P = 0.0065). MSG-infiltrating Foxp3(+) cells were found to positively correlate with biopsy focus score (P = 0.05), infiltrating mononuclear cells, dendritic cells, and macrophages (P </= 0.024 each), and serum C4 levels (P = 0.0328), whereas lower Foxp3(+) cell incidence correlated with adverse predictors for lymphoma development, such as the presence of C4 hypocomplementemia (P = 0.012) and SG enlargement (tendency, P = 0.067). Our findings suggest that the Foxp3(+) T-regulatory cell frequency in the MSG lesions of SS patients correlates with inflammation grade and certain risk factors for lymphoma development.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18818377      PMCID: PMC2570129          DOI: 10.2353/ajpath.2008.080246

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  40 in total

1.  CD4 cytotoxic and dendritic cells in the immunopathologic lesion of Sjögren's syndrome.

Authors:  G Xanthou; N I Tapinos; M Polihronis; I P Nezis; L H Margaritis; H M Moutsopoulos
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

Review 2.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 3.  Natural versus adaptive regulatory T cells.

Authors:  Jeffrey A Bluestone; Abul K Abbas
Journal:  Nat Rev Immunol       Date:  2003-03       Impact factor: 53.106

4.  Control of regulatory T cell development by the transcription factor Foxp3.

Authors:  Shohei Hori; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

5.  Functional expression of a costimulatory B7.2 (CD86) protein on human salivary gland epithelial cells that interacts with the CD28 receptor, but has reduced binding to CTLA4.

Authors:  E K Kapsogeorgou; H M Moutsopoulos; M N Manoussakis
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

6.  The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3.

Authors:  C L Bennett; J Christie; F Ramsdell; M E Brunkow; P J Ferguson; L Whitesell; T E Kelly; F T Saulsbury; P F Chance; H D Ochs
Journal:  Nat Genet       Date:  2001-01       Impact factor: 38.330

7.  Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren's syndrome.

Authors:  John P A Ioannidis; Vassilios A Vassiliou; Haralampos M Moutsopoulos
Journal:  Arthritis Rheum       Date:  2002-03

8.  CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid.

Authors:  Jocea M R van Amelsfort; Kim M G Jacobs; Johannes W J Bijlsma; Floris P J G Lafeber; Leonie S Taams
Journal:  Arthritis Rheum       Date:  2004-09

9.  Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma.

Authors:  Neil A Marshall; Linsey E Christie; Laura R Munro; Dominic J Culligan; Peter W Johnston; Robert N Barker; Mark A Vickers
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

10.  Rates of infiltration by macrophages and dendritic cells and expression of interleukin-18 and interleukin-12 in the chronic inflammatory lesions of Sjögren's syndrome: correlation with certain features of immune hyperactivity and factors associated with high risk of lymphoma development.

Authors:  M N Manoussakis; S Boiu; P Korkolopoulou; E K Kapsogeorgou; N Kavantzas; P Ziakas; E Patsouris; H M Moutsopoulos
Journal:  Arthritis Rheum       Date:  2007-12
View more
  52 in total

1.  Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesis.

Authors:  Gikas E Katsifis; Sofia Rekka; Niki M Moutsopoulos; Stanley Pillemer; Sharon M Wahl
Journal:  Am J Pathol       Date:  2009-08-21       Impact factor: 4.307

2.  Current Aspects of Pathogenesis in Sjögren's Syndrome.

Authors:  Michael Voulgarelis; Athanasios G Tzioufas
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-12       Impact factor: 5.346

3.  Th17/Treg ratio in human graft-versus-host disease.

Authors:  Philippe Ratajczak; Anne Janin; Regis Peffault de Latour; Christophe Leboeuf; Allison Desveaux; Keyvan Keyvanfar; Marie Robin; Emmanuel Clave; Corine Douay; Anne Quinquenel; Claire Pichereau; Philippe Bertheau; Jean Yves Mary; Gérard Socié
Journal:  Blood       Date:  2010-05-18       Impact factor: 22.113

4.  Chitinases in the salivary glands and circulation of patients with Sjögren's syndrome: macrophage harbingers of disease severity.

Authors:  Teresa Greenwell-Wild; Niki M Moutsopoulos; Maria Gliozzi; Efstathia Kapsogeorgou; Zoila Rangel; Peter J Munson; Haralampos M Moutsopoulos; Sharon M Wahl
Journal:  Arthritis Rheum       Date:  2011-10

Review 5.  Primary Sjögren's syndrome: clinical phenotypes, outcome and the development of biomarkers.

Authors:  Andreas V Goules; Athanasios G Tzioufas
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

Review 6.  Pathogenetic mechanisms in the initiation and perpetuation of Sjögren's syndrome.

Authors:  Michael Voulgarelis; Athanasios G Tzioufas
Journal:  Nat Rev Rheumatol       Date:  2010-08-03       Impact factor: 20.543

Review 7.  Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.

Authors:  Michelle L Ratay; Elena Bellotti; Riccardo Gottardi; Steven R Little
Journal:  Adv Healthc Mater       Date:  2017-10-16       Impact factor: 9.933

Review 8.  Effects of Aging in Dry Eye.

Authors:  Cintia S de Paiva
Journal:  Int Ophthalmol Clin       Date:  2017

9.  Serologic features of primary Sjögren's syndrome: clinical and prognostic correlation.

Authors:  Mario García-Carrasco; Claudia Mendoza-Pinto; César Jiménez-Hernández; Mario Jiménez-Hernández; Arnulfo Nava-Zavala; Carlos Riebeling
Journal:  Int J Clin Rheumtol       Date:  2012-12

10.  Sjögren's syndrome-like ocular surface disease in thrombospondin-1 deficient mice.

Authors:  Bruce Turpie; Takeru Yoshimura; Abha Gulati; Jose David Rios; Darlene A Dartt; Sharmila Masli
Journal:  Am J Pathol       Date:  2009-08-21       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.